The USD 1 milestone is a huge achievement in the currency world, and is something every person and business should be aiming to reach. However, there are many ways to do this, and the process can be confusing. So what are the best ways to get there? Here are a few ideas.
Pfizer’s fourth quarter and full year 2021 financial results were strong. A significant number of key milestones were achieved in this period. In particular, Paxlovid and Comirnaty were approved for commercialization and the company completed business development activities. Moreover, Pfizer reported strong dividends per share. The company also raised its 2022 revenue guidance for both Comirnaty and Paxlovid.
In the fourth quarter, Pfizer recognized net losses on equity securities. However, it also reported strong total company financial guidance. Consequently, the company is able to report a higher effective tax rate than the prior-year quarter.
Additionally, Pfizer announced a new gene editing research deal with Beam Therapeutics. Both companies intend to use Beam’s base-editing technology to make changes to single letters of DNA code to cure genetic diseases. Ultimately, they plan to enroll patients in a clinical trial for sickle-cell disease this year.
Shiba Inu is an ERC-20 token designed for use on the Ethereum network. It is one of the hottest cryptocurrencies in the market, and has garnered a lot of attention. Despite its hype, there are a number of reasons to be skeptical.
The first is that the Shiba Inu coin is currently trading at 50% below its all-time high. Even though the value of the coin is still low, it has already seen massive gains over the past 48 hours.
According to Etherscan, the total holder count of the coin is 1,002,021. The Shiba Inu ecosystem is expanding rapidly. At the time of writing, the community had built an army of 2,600 users.
A recent tweet by the Shiba Inu Twitter account emphasized the coin’s accomplishments. The Tweet also mentioned the launch of a card game and a metaverse.
A taxpayer in the know paid $1 million for the services of an investment banker who made the claim he would receive a tidy $10 million upon the close of the deal. This should have been the clincher, but no such luck occurred. The taxpayer’s apprehension was piqued, but not to the degree that they proceeded to sign an engagement agreement. After all, a one-off fee isn’t the type of transaction IRAS is interested in examining, and a full investigation into the matter is no fun.
For the naive, the best course of action is to enlist the assistance of a competent tax professional. If that proves to be fruitless, consider a visit to the IRAS flagship office in Singapore. Or try out a virtual assistant by way of Singpass authentication.
$100M XPRIZE Carbon Removal
The$100M XPRIZE Carbon Removal challenge is a global competition that challenges innovators to develop cost-effective solutions to remove large quantities of carbon dioxide from the atmosphere. Elon Musk, co-founder of Tesla and SpaceX, is funding the competition. He is also providing a $50 million grand prize to one winner.
The competition was launched last year and has screened nearly 500 submissions. Of these, the top 60 teams have been chosen. Each team will receive $1 million to help them scale up their technology. Three runners-up will receive $10 million each.
After a rigorous review process, the judges evaluated each proposal and performance data. They also evaluated cost estimates. All solutions must meet certain criteria to be eligible for the prize. Among these are life cycle analysis, operations plans, and performance data.
The US pharma behemoth Merck has entered into a licensing agreement with Artiva Biotherapeutics, a small startup focused on allogeneic NK cells. Among other things, the deal will see Merck license two off-CD NK cell therapies.
On the heels of this announcement, the company announced that it has successfully closed a $120 million Series B round of financing. This raise was co-led by 5AM Ventures and Medivate Partners, with additional seed funding from private investors. A notable benefactor is GC LabCell, a company that holds a sizable 28% stake in Artiva.
While the GC LabCell name isn’t known to most, the company has been developing NK cell technologies for the better part of a decade. In fact, it was the first to demonstrate safety of allogeneic NK cells in human patients. It also has an off-the-shelf manufacturing platform to help Artiva produce large-scale NK cell therapies.